PLYX Earnings Date: Nov 12, 2026 (Estimated) — Polaryx Therapeutics, Inc. Common Stock

NASDAQ

Updated Oct 30, 2026

Price $1.81

Market Cap $93.5M

P/E -15.2

52W Range $1.75 – $48.91

Next Earnings Nov 12, 2026 · Before open (est.)

When is PLYX's next earnings date?

Polaryx Therapeutics, Inc. Common Stock (PLYX) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 7:07 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06.

How did PLYX do in its last earnings report?

In its most recent report on Aug 13, 2026 (Q2 2026), Polaryx Therapeutics, Inc. Common Stock posted EPS of -$0.03 versus the -$0.04 estimate, a beat of 25.0%. Revenue was $0. The stock's 1-day post-earnings move was +4.0%.

How much does PLYX stock move after earnings?

PLYX beat EPS estimates in 1 of its last 2 reported quarters. Over the last 2 reports the stock moved an average of 12.9% (up or down) in the day after earnings.

About Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.